Profund Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.98M Sell
10,332
-2,328
-18% -$1.78M 0.29% 51
2025
Q4
$9.77M Buy
12,660
+825
+7% +$560K 0.3% 49
2025
Q3
$6.65M Sell
11,835
-1,078
-8% -$610K 0.22% 75
2025
Q2
$6.78M Buy
12,913
+1,388
+12% +$775K 0.24% 67
2025
Q1
$7.31M Sell
11,525
-1,253
-10% -$862K 0.32% 51
2024
Q4
$9.1M Buy
12,778
+1,075
+9% +$902K 0.33% 48
2024
Q3
$12.3M Sell
11,703
-966
-8% -$1.08M 0.47% 34
2024
Q2
$13.3M Buy
12,669
+1,663
+15% +$1.61M 0.49% 33
2024
Q1
$10.6M Sell
11,006
-683
-6% -$649K 0.41% 38
2023
Q4
$10.3M Buy
11,689
+1,523
+15% +$1.25M 0.44% 39
2023
Q3
$8.37M Buy
10,166
+1,689
+20% +$1.33M 0.46% 35
2023
Q2
$6.09M Buy
8,477
+691
+9% +$533K 0.33% 45
2023
Q1
$6.4M Sell
7,786
-9,430
-55% -$7.11M 0.4% 39
2022
Q4
$12.4M Sell
17,216
-65
-0.4% -$48K 0.81% 18
2022
Q3
$11.9M Sell
17,281
-1,022
-6% -$643K 0.86% 21
2022
Q2
$10.8M Sell
18,303
-2,059
-10% -$1.34M 0.69% 26
2022
Q1
$14.2M Sell
20,362
-4,130
-17% -$2.61M 0.6% 27
2021
Q4
$15.5M Sell
24,492
-2,742
-10% -$1.69M 0.51% 28
2021
Q3
$16.5M Buy
27,234
+61
+0.2% +$37.9K 0.56% 26
2021
Q2
$15.2M Sell
27,173
-932
-3% -$472K 0.51% 31
2021
Q1
$13.3M Sell
28,105
-680
-2% -$331K 0.51% 30
2020
Q4
$13.9M Buy
28,785
+2,332
+9% +$1.26M 0.61% 27
2020
Q3
$14.8M Sell
26,453
-2,457
-8% -$1.49M 0.76% 22
2020
Q2
$18M Buy
28,910
+7,356
+34% +$4.18M 1% 16
2020
Q1
$10.5M Sell
21,554
-7,004
-25% -$2.89M 0.79% 23
2019
Q4
$10.7M Buy
28,558
+2,917
+11% +$981K 0.47% 33
2019
Q3
$7.11M Sell
25,641
-991
-4% -$293K 0.36% 44
2019
Q2
$8.34M Sell
26,632
-1,695
-6% -$564K 0.4% 42
2019
Q1
$11.6M Buy
28,327
+647
+2% +$266K 0.56% 29
2018
Q4
$10.3M Sell
27,680
-6,593
-19% -$2.41M 0.64% 25
2018
Q3
$13.8M Buy
34,273
+2,910
+9% +$1.11M 0.53% 26
2018
Q2
$10.8M Sell
31,363
-1,468
-4% -$459K 0.43% 33
2018
Q1
$11.3M Sell
32,831
-2,195
-6% -$763K 0.45% 32
2017
Q4
$13.2M Sell
35,026
-3,506
-9% -$1.42M 0.51% 33
2017
Q3
$17.2M Buy
38,532
+3,119
+9% +$1.48M 0.72% 21
2017
Q2
$17.4M Sell
35,413
-1,884
-5% -$824K 0.79% 19
2017
Q1
$14.5M Sell
37,297
-2,137
-5% -$792K 0.65% 21
2016
Q4
$14.5M Sell
39,434
-5,394
-12% -$2.05M 0.67% 21
2016
Q3
$18M Sell
44,828
-3,044
-6% -$1.22M 0.86% 16
2016
Q2
$16.7M Sell
47,872
-2,457
-5% -$946K 0.81% 16
2016
Q1
$18.1M Sell
50,329
-11,056
-18% -$4.56M 0.94% 16
2015
Q4
$33.3M Buy
61,385
+762
+1% +$413K 1.58% 9
2015
Q3
$28.2M Sell
60,623
-2,126
-3% -$1.14M 1.61% 8
2015
Q2
$32M Buy
62,749
+788
+1% +$385K 1.33% 10
2015
Q1
$28M Buy
61,961
+3,106
+5% +$1.32M 1.09% 12
2014
Q4
$24.1M Buy
58,855
+5,538
+10% +$2.18M 0.99% 13
2014
Q3
$19.2M Sell
53,317
-289
-0.5% -$96.9K 0.9% 14
2014
Q2
$15.1M Sell
53,606
-11,091
-17% -$3.29M 0.66% 18
2014
Q1
$19.4M Buy
64,697
+10,879
+20% +$3.35M 0.88% 13
2013
Q4
$14.8M Buy
53,818
+9,844
+22% +$2.83M 0.66% 15
2013
Q3
$13.8M Buy
43,974
+3,856
+10% +$1.01M 0.73% 13
2013
Q2
$9.02M Buy
+40,118
New +$9.34M 0.64% 20

Other funds holding REGN

Profund Advisors's REGN Position: Q1 2026 in Review

Profund Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2026, selling an estimated $1.78M and leaving 10,332 shares worth $7.98M. The position accounts for 0.29% of the portfolio, ranked #51.

Profund Advisors first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.3M in Q4 2015. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Profund Advisors held 10,332 shares of Regeneron Pharmaceuticals worth $7.98M as of Q1 2026.
  • Profund Advisors sold 2,328 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.78M.
  • Regeneron Pharmaceuticals made up 0.29% of Profund Advisors's portfolio in Q1 2026, its #51 holding.
  • Profund Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Profund Advisors's Regeneron Pharmaceuticals position peaked at $33.3M in Q4 2015.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.